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Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA-3C) is essential for EBV-mediated immortalization of
human B lymphocytes and regulates both the cell cycle and transcription. Transient reporter gene assays have
implicated a pivotal role for EBNA-3C in the regulation of transcription of the majority of latency-associated
genes expressed during the EBV growth program, including the viral oncoprotein LMP-1. To examine the
regulation of latency gene expression by EBNA-3C, we generated an EBV-positive cell line that inducibly
expresses EBNA-3C. This cell line allowed us to examine expression from the endogenous latency gene
promoters in the context of an actual latent infection and the presence of other EBNA proteins, in particular
EBNA-2, which is presumed to coregulate transcription with EBNA-3C. EBNA-3C induced the expression of
both LMP-1 and LMP-2B mRNAs from the bidirectional LMP-1/LMP-2B promoter. In contrast, no effect was
seen on expression from the common EBNA promoter Cp, which is responsive to EBNA-3C in reporter assays.
Activation of LMP expression was not the consequence of increases in EBNA-2, PU.1 or Spi-B transcription
factors, all of which are believed to be critical for activation of LMP-1. Chromatin immunoprecipitation assays
furthermore indicated that EBNA-3C is present at the bidirectional LMP-1/LMP-2B promoter. These results
indicate that EBNA-3C directly activates the expression of LMP-1 and LMP-2B but is unlikely to significantly
regulate EBNA expression via Cp under normal growth conditions.
Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA-3C) is
one of only six viral proteins known to be essential for EBV to
immortalize primary human B lymphocytes (9, 22, 33, 42, 52,
72). Although the EBNA-3 genes (3A, 3B, and 3C) probably
arose through gene duplication, the sequences of the EBNA-3
proteins are highly divergent, and the fact that both EBNA-3A
and EBNA-3C (but not EBNA-3B) are essential for EBV-
mediated immortalization suggests that their functions have
also diverged. These proteins do have related functions, how-
ever, regulating both cell cycle progression and transcription.
All of the EBNA-3 proteins prevent the G2/M arrest that
normally occurs in response to genotoxic or other agents, re-
portedly due to an association with Chk2 (38). In primary
rodent cells, EBNA-3C can override the retinoblastoma pro-
tein checkpoint in the G1 phase of the cell cycle when coex-
pressed with Ha-Ras (60). EBNA-3C is also reported to reg-
ulate p27 stability through interactions with the E3 ubiquitin
ligase SCFSkp2 (36) and to associate with cyclin A in vitro (37).
The region of EBNA-3C that associates with cyclin A has been
localized to a domain that is moderately conserved between
the EBNA-3 proteins, and preliminary data suggest that
EBNA-3B, but not EBNA-3A, may also bind cyclin A in vitro
(36). Both EBNA-3A and EBNA-3C can function as immor-
talizing oncogenes, cooperating with activated Ras in the trans-
formation of primary rodent fibroblasts (27, 60). This function
requires a motif that mediates interaction with the transcrip-
tional repressor CtBP (73), suggesting that the immortalizing
function of the EBNA-3 proteins may not be totally distinct
from their transcriptional properties.
None of the EBNA-3 proteins appears to bind DNA directly
(32, 68), but all bind to a variety of cellular proteins, some of
which function as general transcriptional regulatory proteins,
including TATA-binding protein (TBP), histone deacetylase 1
(HDAC1), CtBP, DP103, prothymosin , and p300 as well as
SUMO-1 and SUMO-3 (3, 11, 21, 27, 35, 44, 65, 70, 73).
EBNA-3C associates with the sequence-specific DNA-binding
protein J (also known as RBP-J, CBF-1, and CSL), a down-
stream signaling protein in the Notch pathway, and the Ets
transcription factors PU.1 and Spi-B (53, 67, 83, 84). These
cellular transcription factors also interact with EBNA-2 and
mediate its transcriptional activation of three EBV latency
gene promoters, i.e., the LMP-1 promoter, which also serves to
regulate the LMP-2B gene on the opposite DNA strand; the
common promoter for the multicistronic EBNA gene, Cp; and
the LMP-2A promoter (20, 30, 39, 40, 45, 47). The LMP-1 and
LMP-2B transcription start sites are located 266 bases apart,
and their common promoter region directs transcription in
opposing directions (hence the designation bidirectional pro-
moter) (41). These promoters presumably share upstream reg-
ulatory elements that include binding sites for both J and
PU.1. In reporter gene assays, the PU.1 binding site, but not
the J binding site, is essential for EBNA-2-mediated transac-
tivation, although the J site contributes to full activation (30).
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The LMP-2A promoter is located approximately 3.2 kb down-
stream (leftward) of the LMP-1 transcription start site and is
thus distinct from the LMP-2B promoter, and it is used to
transcribe an exon unique to LMP-2A (LMP-2A and LMP-2B
share 11 of their 12 exons) that encodes a 118-amino acid
N-terminal domain containing an immunoreceptor tyrosine-
based activation motif (17, 69). Likewise, the LMP-2B pro-
moter gives rise to the unique LMP-2B 5 exon (4, 41). The
LMP-2A and Cp promoters also contain binding sites for J
that can contribute to transcriptional activation by EBNA-2
(45, 86).
The domain of EBNA-3C that binds J has been delineated
and is conserved among the EBNA-3 proteins, all of which can
bind J (83). In reporter gene assays, this interaction represses
EBNA-2/J-mediated transcription by preventing J from as-
sociating with DNA (43, 53, 64, 67, 76, 83). This finding led to
the hypothesis that the EBNA-3 proteins might mediate feed-
back inhibition of Cp (also regulated by EBNA-2 via J) to
stringently regulate EBNA levels and, in turn, expression of
the LMPs. The first demonstration that EBNA-3C might reg-
ulate LMP-1 came from a study in which EBNA-3C expression
was restored in the EBV-positive Burkitt lymphoma cell line
Raji, whose EBV genomes are deleted for most of the
EBNA-3C open reading frame (1, 2). Specifically, in parental
Raji cells, levels of LMP-1 fall as cells progress to G1 (5, 6),
whereas upon stable expression of EBNA-3C, levels of LMP-1
remain high (2). In reporter gene assays, however, EBNA-3C
can mediate either repression or activation of the LMP-1 pro-
moter through J and PU.1 sites, respectively (43, 53, 67, 76,
83, 84). These effects of EBNA-3C on the LMP-1 promoter
and its associations with J and PU.1 are conserved within the
EBNA-3C homologues encoded by the baboon and rhesus
lymphocryptoviruses (LCVs), which are genetically and biolog-
ically equivalent to EBV in their respective hosts, suggesting
that they play important roles in the LCV life cycle (12, 29, 82).
Though dispensable for B-cell immortalization in vitro by
EBV, the LMP-2 proteins (or at least LMP-2A) are thought to
promote B-cell survival in vivo and thus are critical for EBV
persistence and oncogenic potential (8, 48, 49). LMP-1 is es-
sential for EBV-mediated immortalization and functions as a
constitutively active CD40-like molecule (33, 57, 74). While
LMP-1 is necessary for EBV-mediated immortalization and,
presumably, the establishment of a persistent latent infection,
overexpression of LMP-1 results in cytostasis (15, 23). Thus,
the regulation of LMP-1 expression is likely to be tightly con-
trolled. Indeed, while EBNA-2 is clearly the major transcrip-
tional transactivator of the LMP-1 promoter, both EBNA-LP
and EBNA-3C function as coactivators, and the EBNA-3 pro-
teins can also counter EBNA-2’s effects on transcription me-
diated through J (24, 53, 59, 67, 83, 84). Clearly, therefore,
exploration of a given EBNA’s contribution to transcriptional
regulation must take place in the context of an infection in
which the full complement of the EBV latency-associated tran-
scription factors is present. For this reason, we have engi-
neered Raji cells to inducibly express EBNA-3C to explore the
roles that EBNA-3C plays in the regulation of viral and, po-
tentially, cellular promoters. Using this system, we demon-
strate that induction of EBNA-3C is rapidly followed by an
increase in LMP-1 and LMP-2B expression and that this is
concomitant with an association of EBNA-3C with the bidi-
rectional LMP-1/2B promoter. These findings demonstrate
that EBNA-3C is a bona fide transactivator of this promoter
and suggest that this model system would be suitable for the
analysis of potential regulation of cellular gene expression by
EBNA-3C within latently infected cells.
MATERIALS AND METHODS
Cell culture. Raji cells and their derivatives were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum (HyClone) and 2 mM
L-glutamine. Cells were incubated in a humidified chamber at 37°C with a 5%
CO2 atmosphere.
Plasmids. The pTRE-3C plasmid was created by ligating a SacI/EcoRI frag-
ment of an EBNA-3C cDNA encompassing the entire open reading frame
(ORF) into pTRE (Clontech). To generate a FLAG epitope-tagged protein,
annealed oligonucleotides encoding a FLAG epitope (5-CTAGGGATTACAA
GGATGACGACGATAAGT-3 and 5-CTAGACTTATCGTCGTCATCCTT
GTAATCC-3) were inserted at the XbaI site near the 5 end of the EBNA-3C
ORF to yield pTRE-F3C. The resultant F3C protein contains a single FLAG
epitope inserted between amino acids 10 and 11 of EBNA-3C.
Generation of tetracycline-regulated cell lines. The pTet-Off plasmid (Clontech),
encoding the tetracycline-responsive transcriptional activator (19) and carrying a
neomycin resistance gene, was transfected into Raji cells by electroporation of
8  106 cells in 250 l of complete growth medium with 10 g plasmid DNA in
a 0.4-cm-gap electroporation cuvette, using a Bio-Rad Genepulser II set at 960
F and 250 V. After 48 h, transfected cells were transferred to 96-well plates
(500 to 1,000 cells per well) and selected in 0.8 mg G418 per ml. G418-resistant
cells were expanded and tested for tetracycline-regulated gene expression fol-
lowing transfection with a tetracycline-responsive luciferase reporter gene in the
presence or absence of 5 ng doxycycline per ml. A clone with low luciferase
expression in the presence of doxycycline but high expression in its absence was
selected to generate a tetracycline-regulated EBNA-3C-expressing cell line by
transfection with 10 g of pTRE-3C or pTRE-F3C and 1 g of the puromycin
resistance plasmid pJ6puro (56) as described above. After 2 days, cells were
selected in 0.8 mg G418, 0.5 g puromycin, and 5 ng doxycycline per ml. Each
puromycin-resistant clone was then incubated either with or without 5 ng doxy-
cycline per ml for 2 days and analyzed for doxycycline-regulated expression of
EBNA-3C by immunoblotting with an antibody against EBNA-3C. Clones with
tightly regulated expression of EBNA-3C were selected for further analysis.
Immunoblotting. Equal amounts of protein per sample were separated in a 4
to 15% gradient Criterion Tris-HCl sodium dodecyl sulfate (SDS)-polyacryl-
amide gel (Bio-Rad) and transferred to an Immobilon-P membrane (Millipore).
For EBNA-3 detection, membranes were blocked in Tris-buffered saline con-
taining 0.5% Tween 20 and 5% nonfat dry milk and then incubated with sheep
anti-EBNA-3C or anti-EBNA-3A antibody (Ex-Alpha), followed by incubation
with horseradish peroxidase (HRP)-conjugated rabbit anti-sheep secondary an-
tibody (Chemicon). Proteins were visualized by enhanced chemiluminescence
(Amersham Biotech). LMP-1 and EBNA-2 were detected with mouse anti-
LMP-1 S12 antibody (51) and mouse PE2 antibody (81), respectively, followed by
anti-mouse HRP-conjugated antibody. PU.1 and Spi-B were detected with an-
tibodies T21 and N16, respectively (Santa Cruz Biotechnology). Membranes
were subsequently stripped by incubation in 100 mM -mercaptoethanol, 2%
SDS, and 62.5 mM Tris-HCl (pH 6.8) at 52°C for 30 min and then reprobed with
mouse anti-actin (clone JLA20; Calbiochem) followed by sheep anti-mouse
HRP-conjugated antibody (Amersham Biosciences).
RNA (Northern) blot analysis. Cells were incubated in the presence or ab-
sence of doxycycline for 5 days, after which total RNA was extracted using
RNA-Bee according to the manufacturer’s instructions (Tel-Test). RNAs were
fractionated in a 1.2% agarose gel containing formaldehyde in morpholinepro-
panesulfonic acid (MOPS) buffer. Following electrophoresis, RNAs were trans-
ferred to a GeneScreen Plus membrane (Perkin-Elmer) by capillary transfer in
10 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate [pH 7.0]). The
membrane was prehybridized in 50% formamide, 5 SSPE (1 SSPE is 150 mM
NaCl, 10 mM sodium phosphate [pH 7.4], and 1 mM EDTA), 5 Denhardt’s
solution, 1% SDS, and 0.1 mg denatured salmon testis DNA (Sigma) per ml at
45°C for 6 h. The membrane was then hybridized in the same solution with a
32P-labeled (by nick translation) LMP-1 cDNA overnight at 45°C. The mem-
brane was then washed at 62°C with decreasing concentrations of SSC (2 to
0.5) containing 1% SDS and processed by phosphorimage analysis. The mem-
brane was then reprobed for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as a loading control.
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ChIP assay. Raji Tet-Off-EBNA-3C cells (5  107 to 8  107) were cultured
in the presence or absence of doxycycline for 48 h. Chromatin immunoprecipi-
tation (ChIP) was then performed using a ChIP-IT chromatin immunoprecipi-
tation kit (Active Motif). Briefly, protein-DNA complexes were cross-linked for
10 min at room temperature in RPMI 1640 medium containing 1.1% formalde-
hyde. Cross-linking was terminated by the addition of glycine, cells were pelleted
by centrifugation and then lysed, and the extract was sonicated to shear the DNA
to sizes ranging between 200 and 1,000 base pairs in length. Total cell extracts
were precleared with protein G agarose beads and then subjected to immuno-
precipitation with an antibody to EBNA-3C (ExAlpha) or the immunoglobulin G
(IgG) and anti-TFIIB controls provided with the kit. A fraction of the precleared
chromatin samples was saved to represent input DNA. Immunoprecipitated
DNA was then purified following reversal of cross-linkage to protein according
to the manufacturer’s instructions and was amplified by PCR using primers for
the Raji LMP-1 promoter (GenBank accession no. M20868). The forward and
reverse primer sequences were 5-CTACGGTGAACCCACATCCT-3 and 5-
CGGTGTGTGTGTGCATGTAA-3, respectively, and yielded a product of 365
bp. GAPDH primers were provided with the ChIP-IT kit. PCR was performed
using ReddyMix PCR master mix (ABgene) containing 1.25 units Taq DNA
polymerase, 75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 1.5 mM MgCl2,
0.01% Tween 20, a 200 M concentration of each deoxynucleoside triphosphate,
dye for electrophoresis, a 500 nM concentration of each primer, and 3.75 Ci
[-32P]dCTP (10 mCi/ml; NEN/Perkin-Elmer) per reaction mixture. Following
an initial denaturation step at 94°C for 2 min, DNA was amplified by a variable
number of cycles of 94°C for 20 seconds, 61.9°C for 1 min, and 72°C for 60
seconds, followed by a final extension step at 72°C for 7 min. PCR products were
fractionated by electrophoresis in a nondenaturing 5% acrylamide gel that was
then vacuum dried and processed by phosphorimage analysis for quantification
(STORM 860; Molecular Dynamics).
Reverse transcription-PCR (RT-PCR) analysis of LMP-2B and EBNA-3C
RNAs. Raji Tet-Off-EBNA-3C cells were cultured in the presence or absence of
5 ng doxycycline per ml for 24 or 48 h. For each experimental time point,
approximately 107 cells were washed twice with ice-cold phosphate-buffered
saline, and total RNA was isolated with RNA-Bee according to the manufactur-
er’s protocol (Tel-Test). RNAs were treated with 10 U of RNase-free DNase
(Promega) and 100 U of RNasin (Promega) for 15 min at 37°C, followed by
extraction in phenol-chloroform and precipitation in ethanol. RNAs were re-
verse transcribed to cDNAs by using an Advantage RT-for-PCR kit (BD Bio-
sciences) according to the manufacturer’s instructions. Primers for GAPDH
were included in the kit. The forward and reverse primers used to amplify
LMP-2B cDNA (GenBank accession no. AJ507799) had the sequences 5-CAA
CGTTGGGAGGTCGTTGG-3 and 5-AAGCCAGTAGCAGCAGCGTC-3,
corresponding to sequences in exons 1 and 4, respectively, and yielded a 528-bp
product. The forward and reverse primers for EBNA-3C (GenBank accession
no. AJ507799) had the sequences 5-CTGGCAAAACTTGCTCCA-3 and 5-G
TGCTTCTGCCTTATCAGA-3, respectively, and yielded a 499-bp product.
PCR was performed as indicated above for ChIP assays, except that the anneal-
ing step in each cycle was 50.5°C for 90 seconds. The mRNA level of each sample
was normalized to the signal obtained from GAPDH mRNA products.
RESULTS
EBNA-3C activates LMP-1 protein expression. To examine
the transcriptional properties of EBNA-3C in a biologically
relevant setting, a Raji BL cell system was selected because
stable expression of EBNA-3C (whose gene is deleted from
EBV genomes in Raji cells) increases the expression of LMP-1
from its endogenous viral promoter in the presence of the
complete complement of latency proteins (1, 2). We engi-
neered an inducible EBNA-3C expression cassette in Raji cells
that is controlled by a tetracycline-regulated promoter. Several
clones were selected in which EBNA-3C expression was unde-
tectable in the presence of the tetracycline derivative doxycy-
cline (i.e., Tet off) but was readily induced upon removal of
doxycycline. To determine whether induction of EBNA-3C
expression affected the level of LMP-1, an immunoblot was
stripped and reprobed with an LMP-1-specific monoclonal an-
tibody. Clearly, LMP-1 levels were substantially increased in
the EBNA-3C-expressing cells (Fig. 1A). Furthermore, cells
expressing EBNA-3C and LMP-1 underwent a dramatic phe-
notypic change: whereas parental Raji or uninduced cells grew
as single cells or in small clusters, EBNA-3C-expressing Raji
cells grew in large clumps (Fig. 1B), a characteristic feature of
lymphoblastoid cell lines (LCLs) and LMP-1-expressing cells.
These results were consistent with those of Allday et al. for
stable expression of EBNA-3C (1) and suggested that the in-
crease in LMP-1 was likely to be a specific effect of EBNA-3C
and not a compensatory change that occurred to promote cell
survival during selection for a cell line that stably expressed
EBNA-3C. The doxycycline-regulated expression of EBNA-3C
in Raji cells therefore represents an ideal system with which to
further explore EBNA-3C-regulated gene expression.
To determine the time course of EBNA-3C expression,
EBNA-3C was monitored by immunoblot analysis at various
times after the removal of doxycycline. EBNA-3C was detect-
able 4 h following the removal of doxycycline and attained
maximal expression at approximately 12 h (Fig. 2). To evaluate
the effect of EBNA-3C on LMP-1 expression, LMP-1 levels
were monitored at the same time points. In the parental cell
line, Raji-Tet-off, LMP-1 levels were relatively low and exhib-
ited a reproducible decrease after 24 to 48 h. Similar decreases
have been reported previously for Raji cells; LMP-1 levels are
increased in the presence of serum and have been demon-
strated to fall with time in culture (5, 6). As expected, doxycy-
cline had no effect on the level of LMP-1. For the EBNA-3C-
inducible cell line analyzed in parallel in the presence of
doxycycline (i.e., in the absence of EBNA-3C), the levels of
LMP-1 were low and comparable to those in the parental Raji
cell line at each time point, exhibiting a similar decrease after
24 h. Following the induction of EBNA-3C expression, some
increases in LMP-1 levels could be seen at early times (i.e., 2 to
4 h) that were coincident with changes in EBNA-2 that may
not be explained entirely by differences in protein loading. The
most striking differences, however, were seen beginning at
12 h, when EBNA-3C is maximally expressed, and continuing
FIG. 1. EBNA-3C activates expression of the LMP-1 protein. Ex-
pression of EBNA-3C was induced by growing cells in the absence of
doxycycline for 5 days. (A) Expression of EBNA-3C, LMP-1, and actin
was determined by immunoblot analysis. (B) Cells that were not in-
duced (left) or induced to express EBNA-3C (right) were examined by
light microscopy.
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through the later time points. By 12 h, LMP-1 levels were
significantly increased in cells expressing EBNA-3C, indepen-
dent of any changes in EBNA-2. In cells that did not express
EBNA-3C, LMP-1 levels began to decrease after this time,
whereas LMP-1 levels were at least partially sustained in cells
that expressed EBNA-3C. As the levels of EBNA-3C began to
decline with time, there was a corresponding decrease in the
levels of LMP-1, providing further evidence that increases in
LMP-1 are dependent on EBNA-3C.
EBNA-3C does not overtly regulate expression from Cp.
Previous studies based on transient reporter assays have dem-
onstrated an ability of EBNA-3C to down-regulate expression
from the EBNA promoter Cp (64). The mRNAs encoding the
six EBNA proteins are generated from a large primary tran-
script originating at Cp that is processed into the individual
mRNAs. It has therefore been suggested that EBNA-3C might
control overall EBNA gene expression through feedback re-
pression. A previous study that analyzed promoter usage in
various cell lines suggested that Raji cells might not use Cp
(78); an alternative explanation, however, is that the oligonu-
cleotides used did not hybridize to RNAs in Raji cells due to
differences in sequence from the prototypical EBV, B95-8.
Using RT-PCR analysis, we have clearly demonstrated that Cp
is used in Raji cells (D. Hughes, J. Sample, and C. Sample,
unpublished observations). To determine whether EBNA-3C
regulated Cp-driven EBNA expression in the context of a la-
tent infection, the levels of EBNA-2 were examined by immu-
noblotting 2 to 96 h after the induction of EBNA-3C expres-
sion. As shown in Fig. 2 (bottom panels), although we observed
some variations in EBNA-2 levels in the presence and absence
of doxycycline at some time points (i.e., 4 h) that did not
appear to be due to unequal protein loading, overall we did not
see a consistent effect of EBNA-3C on EBNA-2 levels, and
specifically saw no decrease in EBNA-2 levels associated with
EBNA-3C expression, throughout the time course experiment.
We also examined whether EBNA-3C affected the expression
of a second protein expressed from Cp, EBNA-3A. Consistent
with our analysis of EBNA-2, EBNA-3C had no effect on the
level of EBNA-3A, even when overexpressed relative to
EBNA-3C levels in the LCL IB4 (Fig. 3). Taken together,
these findings suggest that in the presence of the other EBNA
proteins in an actual latent infection, EBNA-3C expression has
little or no negative effect on Cp, as predicted from earlier
studies measuring EBNA-3C’s influence on Cp within a re-
porter plasmid and in the presence of EBNA-2 in EBV-nega-
tive cells.
EBNA-3C expression results in increased levels of LMP-1
and LMP-2B mRNAs. To determine whether the increase in
LMP-1 protein was the result of an increased level of LMP-1
mRNA, we performed Northern blot analysis of RNAs from
EBNA-3C-expressing versus non-EBNA-3C-expressing Raji
cells. In the absence of EBNA-3C, LMP-1 mRNA levels were
low. Following induction of EBNA-3C expression, levels of
LMP-1 mRNA were increased approximately fivefold, whereas
FIG. 2. Time course of EBNA-3C and LMP-1 induction. Raji Tet-off-3C cells (upper panel) were cultured in the presence or absence of
doxycycline and harvested at different time points. SDS-polyacrylamide gel electrophoresis was performed in triplicate. Each immunoblot was
stripped and reprobed for actin. Parallel experiments were performed with the Raji Tet-off parental cell line (lower panel). Mock induction refers
to the absence of doxycycline (), which would induce EBNA-3C in Raji Tet-off-3C cells; cells incubated in the presence of doxycycline, which
would not induce EBNA-3C, are represented by “	.”
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there was no change in the GAPDH mRNA level (Fig. 4).
Thus, an increase in LMP-1 protein correlates with an increase
in mRNA, as one would expect if EBNA-3C transactivates the
endogenous LMP-1 promoter.
EBNA-2 has been shown to activate the expression of both
LMP-2A and LMP-2B in reporter gene assays as well as by
exogenous expression in the EBV-positive cell line P3HR1,
which lacks EBNA-2 as a consequence of deletion (40, 55, 87).
For EBV-negative cells, reporter gene assays suggest that the
EBNA-3 proteins repress expression from the LMP-2A pro-
moter (43), but whether these proteins also affect LMP-2B
expression has not been examined. In Raji cells, expression
from the endogenous LMP-2A promoter cannot be examined
due to the deletion of the promoter and the first exon (25, 62).
The LMP-1/2B bidirectional promoter (diagrammed in Fig.
5A), however, is intact, and we reasoned that EBNA-3C could
coordinately regulate the expression of both genes or might
preferentially regulate LMP-1 expression. Because there are
no antibodies available with which to effectively monitor LMP-
2B, we employed an RT-PCR-based approach to determine
whether EBNA-3C also influences LMP-2B expression. In the
absence of EBNA-3C (in the presence of doxycycline),
LMP-2B mRNA was undetectable but was easily amplified
upon induction of EBNA-3C both 24 and 48 h after the re-
moval of doxycycline (Fig. 5B). Note that the multiple bands
appearing at the 24-h time point are not reproducible and thus
are not reflective of distinct RNA structures present at this
time point. The increases in LMP-2B mRNA ranged from 3.4-
to 6.1-fold in four separate experiments. This clearly demon-
strated that EBNA-3C activates the expression of both genes
from the LMP-1/2B bidirectional promoter, suggesting that its
effect is likely exerted on the promoter itself.
EBNA-3C does not induce expression of known cellular
transactivators of the LMP-1 promoter. Having shown that
EBNA-3C can clearly up-regulate the expression of LMP-1
and LMP-2B mRNAs in the context of a latent EBV infection,
we next began to address the most likely mechanism of
EBNA-3C action in this regard. One possibility is that
EBNA-3C increases the levels of viral or cellular transcription
factors that activate expression from the bidirectional pro-
moter. Clearly, the level of the major viral transactivator
EBNA-2, which is expressed from Cp, is not notably affected by
EBNA-3C (Fig. 2). In reporter gene assays, the PU.1 binding
site is essential for EBNA-2-mediated activation of LMP-1 and
also for the activation mediated through EBNA-3C in conjunc-
tion with EBNA-2 (30, 84). Thus, PU.1 and the closely related
Ets family member Spi-B are the cellular factors that bind to
the LMP-1 promoter, and they are believed to be critical for
transactivation of LMP-1 expression (30, 39). The levels of
PU.1 and Spi-B were therefore analyzed by immunoblotting
following the induction of EBNA-3C expression. As shown in
Fig. 6, EBNA-3C had no effect on the level of either PU.1 or
Spi-B.
EBNA-3C interacts with the bidirectional LMP-1/2B pro-
moter. Although EBNA-3C alone has no known specific DNA-
binding capability, EBNA-3C expressed in cellular extracts can
FIG. 3. EBNA-3C does not affect the level of EBNA-3A. Raji
Tet-off-3C cells were cultured for 48 h in the presence or absence of
doxycycline. A sample of IB4 cells (an LCL) was included as a control.
Immunoblots were performed for the indicated proteins and reprobed
for actin.
FIG. 4. EBNA-3C increases expression of LMP-1 mRNA. LMP-1
mRNA was detected by Northern blot analysis of total RNA isolated
from Raji Tet-off cells expressing () or not expressing (	) EBNA-3C.
The blot was stripped and reprobed for GAPDH as a loading control.
FIG. 5. EBNA-3C activates expression of LMP-2B mRNA.
(A) Schematic of LMP-1/LMP-2B bidirectional promoter. Binding
sites for the transcription factors J and PU.1 are shown. Boxes below
the map depict the mRNAs for LMP-1 and LMP-2B (not to scale),
showing coding (black boxes) and noncoding (white boxes) exons.
(B) Raji Tet-off EBNA-3C cells were induced to express EBNA-3C,
and cells were harvested 24 or 48 h later. Total RNA was isolated, and
primers specific for LMP-2B, EBNA-3C, and GAPDH were used to
determine the level of each mRNA by RT-PCR, using [-32P]dCTP in
the reaction mix for quantification.
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bind to DNA (32, 68). This result suggests that EBNA-3C
might be targeted indirectly to DNA, and in support of this
possibility, EBNA-3C associates with a variety of transcription
factors, including PU.1 (3, 65, 67, 83, 84). Therefore, we next
examined whether the induction of LMP-1 and LMP-2B ex-
pression by EBNA-3C was a result of its interaction with the
bidirectional promoter via such a protein-protein interaction.
To investigate this possibility, we performed a ChIP assay to
determine whether EBNA-3C is indeed present on the pro-
moter following its induction of expression. As shown in Fig. 7,
an antibody to EBNA-3C or TFIIB (positive control), but not
an irrelevant IgG (negative control), immunoprecipitated
DNA from the LMP-1 promoter. Furthermore, LMP-1 pro-
moter DNA was enriched 10.9-fold in immunoprecipitates
from cells in which EBNA-3C expression had been induced
relative to those from cells in which EBNA-3C had not been
induced, whereas DNA from the EBNA-1-specific promoter
Qp, used as a negative control, was only enriched 1.7-fold.
Thus, the activation of LMP-1 and LMP-2B expression by
EBNA-3C is most likely mediated through direct activation of
transcription from the LMP-1/2B bidirectional promoter.
DISCUSSION
Although EBNA-3C is essential for EBV-mediated immor-
talization of B cells, its specific contribution is not fully under-
stood. The first function reported for EBNA-3C was the ability
to increase LMP-1 protein levels in clones of the EBV-infected
cell line Raji that stably expressed EBNA-3C (1, 2). These and
other studies (77) suggested that EBNA-3C could function as
a transcription factor, which was later confirmed (43, 44, 53, 67,
76, 83, 84). However, given anecdotal evidence that EBNA-
3C-expressing cell lines are difficult to obtain, suggesting that
the protein might be toxic, it was possible that a compensatory
increase in LMP-1, which prevents apoptosis (26), had been
selected for during establishment of the cell lines. By using a
cell line that expressed EBNA-3C in an inducible fashion, we
were able to determine that the increase in LMP-1 protein
occurred only hours after EBNA-3C expression, suggesting
that this is a specific effect of EBNA-3C and demonstrating
that this occurred not only in growth-arrested cells, as previ-
ously described, but also in proliferating cells. As previously
reported, LMP-1 levels are increased by serum and fall over
time in culture (5, 6). The increases seen with EBNA-3C are
largely due to sustained levels of LMP-1 at later time points.
Our inducible cell line therefore offered a unique opportunity
to further explore the mechanism through which EBNA-3C
functions in the presence of the other latency-associated pro-
teins. The inclusion of all latency-associated proteins is essen-
tial because recent studies indicated that EBNA-LP, like
EBNA-3C, can serve as a coactivator of EBNA-2-mediated
transcription; for EBNA-LP, coactivation is most likely medi-
ated through interactions with Sp100 (24, 46, 59). While
EBNA-2 activates expression from the common EBNA (Cp),
LMP-2A, and LMP-1/2B promoters, EBNA-LP selectively reg-
ulates a subset of these promoters, i.e., Cp and LMP-1/2B but
not LMP-2A (61). As shown here, EBNA-3C activates expres-
sion from the LMP-1/2B promoter in the presence of EBNA-2
and -LP, but not that from Cp. Thus, although both EBNA-LP
and EBNA-3C serve as coactivators of EBNA-2, they can reg-
ulate different subsets of promoters. Moreover, EBNA-3C ac-
tivated expression from the LMP-1/2B promoter even in the
presence of EBNA-LP, suggesting that each operates through
a distinct mechanism.
Given the essential contribution of LMP-1 to EBV-mediated
transformation, the ability to regulate LMP-1 is likely an im-
portant function of EBNA-3C. While reporter gene assays with
EBV-negative cell lines have yielded conflicting results as to
whether EBNA-3C activates or represses LMP-1 expression
(53, 67, 83), EBNA-3C expression led to a substantial increase
in the amount of LMP-1 protein in Raji cells. Furthermore,
there was a corresponding increase, not only in the LMP-1
FIG. 7. EBNA-3C interacts with the bidirectional LMP-1/LMP-2B
promoter. Raji Tet-off-3C cells were induced to express EBNA-3C by
removal of doxycycline from the growth medium () for 48 h or were
kept under doxycycline repression (	). A ChIP assay was performed to
examine the association of EBNA-3C with the LMP-1/LMP-2B pro-
moter (upper panel). The chromatin was immunoprecipitated using an
antibody specific for EBNA-3C. As a positive control, the chromatin
was immunoprecipitated with an antibody to TFIIB, a known element
of the basal transcriptional machinery which associates with the
GAPDH promoter (lower panel) and also with the LMP-1 promoter.
As a negative control, the chromatin was immunoprecipitated with an
irrelevant IgG. The GAPDH and LMP-1 primers correspond to PCR
primers to amplify the promoter sequences of these genes. Negative
control primers were designed to span sequences outside the GAPDH
promoter area with which TFIIB is associated.
FIG. 6. EBNA-3C does not affect the level of PU.1 or Spi-B. Ex-
tracts from Raji Tet-off cells expressing () or not expressing (	)
EBNA-3C and from the parental cell line Raji Tet-off were analyzed
for levels of the transcription factors PU.1 and Spi-B, which are key
activators of the LMP-1 promoter.
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message but also in the amount of LMP-2B message, which is
transcribed in the opposite direction and presumably con-
trolled by the same regulatory elements in the LMP-1/2B bi-
directional promoter. This coordinated regulation, together
with the results of reporter gene assays, strongly suggests that
EBNA-3C regulates the transcription of these two distinct
latency-associated genes. Further evidence to support this con-
clusion was obtained from our ChIP assays, whose results sug-
gested that EBNA-3C is associated with the LMP-1/2B bidi-
rectional promoter when LMP-1 and LMP-2B are expressed.
Because EBNA-3C has no demonstrable specific DNA-bind-
ing capability (68), it is likely that its interaction with the
promoter is mediated through interactions with cellular tran-
scription factors. Indeed, our previous studies have demon-
strated that EBNA-3C can interact with the transcription fac-
tor PU.1, known to be essential for activation of the LMP-1
promoter by EBNA-2 (30), and can activate the expression of
reporter genes controlled solely through PU.1 binding sites
(84). Although other mechanisms could be envisioned to ac-
count for this observation (such as the removal of a repressor
from PU.1), these data collectively suggest that EBNA-3C is
targeted to DNA through associations with PU.1. Like that of
other Ets family members, the activity of PU.1 is regulated
through associations with other transcription factors (58). The
most notable examples are the Ig  and 
 3 enhancers, to
which PU.1 recruits IRF-4 to activate transcription (13, 63).
This activity is repressed by the association of PU.1 with BSAP,
a protein essential for proper B-cell development (50). More
recently, it was reported that PU.1 associates with HDAC1,
which leads to a repression of transcription (34). EBNA-3C
might be targeted to DNA solely through associations with
PU.1 (or other cellular proteins) or may make contacts with
the DNA through, for example, the basic domain located in its
amino terminus. These associations may perturb the interac-
tion of PU.1 with other cellular transcription factors, known or
novel, that regulate its function or may recruit additional tran-
scription factors to the promoter.
EBNA-3C’s function as a transcription factor has been stud-
ied previously using reporter gene assays, and the results dem-
onstrated that EBNA-3C (in addition to EBNA-3A and
EBNA-3B) can repress activation mediated through EBNA-2/
J. J is a highly conserved protein, and the activity of the
Drosophila melanogaster homologue, Suppressor of Hairless
[Su(H)], is controlled by Hairless, a protein that regulates
Su(H) activity in a manner similar to that of the EBNA-3
proteins observed in reporter gene assays, i.e., Hairless re-
presses Su(H) activity (7). Given the precedent for this type of
regulation, the hypothesis was developed that EBNA-3C pre-
vents overexpression of the latency-associated proteins by re-
pression of the EBNA (Cp), LMP-1, and LMP-2A promoters.
Since all of the EBNAs are expressed from Cp, a widely ac-
cepted model arose in which the EBNA-3 proteins regulated
Cp by a feedback repression mechanism, thereby preventing
overexpression of LMP-1, which would lead to cytostasis. Al-
though this is an appealing hypothesis, no evidence for repres-
sion of either Cp or the bidirectional LMP-1/2B promoter was
seen in our system. Although EBNA-3C is not present in Raji
cells, EBNA-3A and EBNA-3B are expressed, so it is possible
that some repression is indeed exerted by these other members
of the EBNA-3 family. However, studies of EBV-immortalized
cell lines suggest that the level of J exceeds that of the EBNA
proteins (31). Thus, in an EBV-infected cell, the EBNAs may
not compete for J, whereas in transient transfection assays
(where the highly overexpressed EBNA proteins are likely to
be in considerable excess of endogenous J) the substantially
higher levels of EBNA proteins may result in competition for
the available J. In support of the supposition that EBNA-3C
does not routinely regulate expression from Cp, recombinant
EBV strains carrying a mutation of the J sites in Cp or a
deletion of Cp are able to immortalize B lymphocytes, and the
resulting LCLs express normal levels of EBNA proteins, as do
two naturally occurring lymphoblastoid cell lines that have
deleted Cp (14, 71, 79, 80). It is possible that repression
through J might be a fail-safe mechanism for controlling Cp,
such that if transcription reached an extremely high level, the
EBNA-3 proteins could restore transcription to a suitable
level.
Together, these results raise the question of the function of
the J binding sites in Cp and of the J binding domain in each
EBNA-3 protein. Clearly, the J protein plays a prominent
role in EBV biology. EBNA-2 is targeted to DNA through its
interactions with J, converting an inhibitory protein-DNA
complex into an activating one (28, 75, 85). Binding sites for J
are conserved in the Cp, LMP-1/2B, and LMP-2A promoters
of EBV-like LCVs (16, 18, 66). Likewise, the J binding do-
main is conserved in the EBNA-3 homologues of these LCVs,
suggesting that this domain serves an important function (12,
29, 82). Two other studies support this conclusion. In an EBV-
transformed B-cell line, three- to fivefold overexpression of
EBNA-3A results in growth arrest at the G0/G1 stage of the
cell cycle, whereas EBNA-3A containing an inactivating mu-
tation in the J binding domain failed to arrest cells (10). More
significantly, studies in an LCL containing a conditional
EBNA-3A mutant demonstrated that wild-type EBNA-3A
could support continued proliferation after inactivation of the
endogenous EBNA-3A protein, whereas EBNA-3A with a mu-
tation in the J binding domain could not (54). Collectively,
these data suggest an important function of the J binding
domain in each EBNA-3 protein. The interaction with J may
normally be involved in the activation of LMP-1 in a way that
is not manifested in reporter gene assays, but such a function
would have to involve a mechanism that is unique to EBNA-3C
because we have previously demonstrated that neither
EBNA-3A nor EBNA-3B can activate the LMP-1 promoter
(84). The association with J may also be involved in the
regulation of cellular genes by EBNA-3C. Alternatively, the
interaction with J may serve an as yet unknown purpose. Our
model system provides an ideal model for investigating these
possibilities.
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